logo

For the Inventor, By the Inventor

Mainz, Germany

Dirk Seiffge

This inventor holds 24 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Hoechst Aktiengesellschaft, Aventis Pharma Deutschland, Gmbh, Glycorex Ab. Active years: 1987-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dirk Seiffge. Retrieved from https://idiyas.com/inventor/dirk-seiffge

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 24

% Patents Active = 95.8

Average Co-Inventor Count = 3.3

ph-index = 10

Forward Citations = 415(Granted Patents)


Location History:

  • Munzenberg, DE (1987 - 1991)
  • Mainz, DE (1993 - 1996)
  • Mainz-Kostheim, DE (1996 - 2005)

Company Filing History:

goldMedal16 out of 6,705 
 
Hoechst Aktiengesellschaft
 patents
silverMedal6 out of 330 
 
Aventis Pharma Deutschland, Gmbh
 patents
bronzeMedal1 out of 7 
 
Glycorex Ab
 patents
4. 1 out of 18 
 
Hoechst Marion Roussel Deutschland Gmbh
 patents

Years Active: 1987-2005

Loading Chart...
Areas of Expertise:
Imidazolidine Derivatives
Leucocyte Adhesion
Antiadhesive Compounds
Pharmaceutical Preparations
Heterocyclic Compounds
Spiroimidazolidine
Carbohydrate Mimetics
Pyridopyrimidinediones
Lipid-Selective Antioxidants
Fucosylated Dicarboxylic Acids
Piperidine Carboxylic Acids
Malonic Acid Derivatives
24 patents (USPTO):Explore Patents
1. 6838439 - Heterocytes as inhibitors of leucocyte adhesion and as VLA-4 antagonists (2005-01-04),
2. 6759424 - Imidazolidine derivatives, their preparation, their use, and pharmaceutical preparations comprising them (2004-07-06),
3. 6521654 - Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them (2003-02-18),
4. 6514952 - Hydantoin derivatives as inhibitors of leucocyte adhesion and as VLA-4 antagonists (2003-02-04),
5. 6423712 - 2,4-Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them (2002-07-23),
6. 6399643 - Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations formed therefrom (2002-06-04),
7. 6331552 - Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them (2001-12-18),
8. 6136790 - Carbohydrate mimetics having antiadhesive properties (2000-10-24),
9. 6034238 - Heterocyclic compounds, their preparation and their use as leucocyte (2000-03-07),
10. 5998447 - Heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists (1999-12-07),
11. 5858994 - Carbohydrate conjugates as inhibitors of cell adhesion (1999-01-12),
12. 5811405 - Multiply fucosylated dicarboxylic acids possessing antiadhesive (1998-09-22),
13. 5739300 - Antiadhesive piperidine-and pyrrolidinecarboxylic acids (1998-04-14),
14. 5693621 - Malonic acid derivatives having antiadhesive properties (1997-12-02),
15. 5556854 - Pyridopyrimidinediones, processes for their preparation and their use as (1996-09-17),

Title: **Dirk Seiffge: Innovator in Leukocyte Adhesion Inhibition**

Introduction

Dirk Seiffge, based in Mainz-Kostheim, Germany, is an accomplished inventor with a significant portfolio of 24 patents. His work predominantly focuses on the development of novel compounds aimed at improving health outcomes, particularly in relation to inflammatory processes and diseases caused by excessive leukocyte adhesion.

Latest Patents

Among Dirk Seiffge's most recent innovations are two notable patents. The first patent deals with heterocytes that act as inhibitors of leukocyte adhesion and as VLA-4 antagonists. This invention details compounds that inhibit the adhesion and migration of leukocytes, which can be revolutionary in treating conditions like rheumatoid arthritis and allergic disorders by interfering with the VLA-4 receptor's interactions with its ligands. The second patent involves imidazolidine derivatives, detailing their preparation, usage, and inclusion in pharmaceutical formulations, further broadening the therapeutic possibilities in treating complex diseases.

Career Highlights

Throughout his career, Dirk has worked with prominent companies including Hoechst Aktiengesellschaft and Aventis Pharma Deutschland GmbH. His extensive experience in the pharmaceutical industry has provided him with a robust foundation to drive his innovative endeavors and contribute significantly to medical science.

Collaborations

Dirk has collaborated with esteemed colleagues such as Hans Ulrich Stilz and Volkmar Wehner, facilitating a synergistic approach to innovation that leverages shared expertise and insights in the field of pharmaceutical development.

Conclusion

In conclusion, Dirk Seiffge stands out as a significant figure in the innovative landscape of pharmaceutical science. His dedication to developing cutting-edge solutions for health challenges demonstrates the critical intersection of invention and patient care. With a robust portfolio of patents, Seiffge continues to influence the future of medical treatment and research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…